FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 28, 2018--
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Laura Hamill
will join the company as Executive Vice President, Worldwide Commercial
Operations, and will become a member of Gilead’s senior leadership team.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180828005831/en/
Laura Hamill - Executive Vice President, Worldwide Commercial Operations, Gilead Sciences (Photo: Business Wire)
Ms. Hamill is an experienced leader with significant expertise in
managing the complexity of commercial operations at a large
biopharmaceutical company, including driving strategic planning,
delivering operating results, executing on product launches and
strategic partnerships, and leading market development. Ms. Hamill joins
Gilead from Amgen, where she most recently served as Senior Vice
President, U.S. Commercial Operations and oversaw the launch of multiple
products across new and existing therapeutic areas. Throughout her
career, she worked across the organization in numerous executive roles,
with responsibility for a diversity of functions, including general and
regional management, U.S. reimbursement and access, and manufacturing.
She has a breadth of experience around the world, in regions such as the
United States, Europe, Australia, Canada, Turkey, the Middle East and
Latin America. In addition to her executive positions at Amgen, Ms.
Hamill served as a board member of the Amgen Foundation and was the
executive leader of the company’s Senior Women’s Advisory Council. She
currently serves on the Advisory Board of the Women Business Leaders of
the U.S. Health Care Industry Foundation.
Prior to Amgen, Ms. Hamill held a variety of roles in the
biopharmaceutical industry, including positions at Hoffmann La-Roche and
Klemtner Advertising. She has a degree in business administration from
the University of Arizona.
“Over the past several months, we have conducted an extensive search for
a new leader and we believe that Laura brings to Gilead the kind of
operational rigor and organizational experience that will help us as we
seek to build on our position of strength in existing therapeutic areas
and introduce products in new ones,” said John F. Milligan, PhD,
President and Chief Executive Officer of Gilead. “She has repeatedly
demonstrated an ability to transform infrastructure and capabilities to
drive innovation and business performance. Most importantly, she shares
Gilead’s vision of advancing treatments that dramatically improve the
lives of people with life-threatening illnesses, and we believe that her
skills and expertise will complement that of other Gilead leaders as we
move into the future with our next generation of medicines.”
“I have worked in the biopharmaceutical industry for many years and I am
impressed with the quality of products in all stages of development at
Gilead and with the company’s ability to execute on partnerships and
deals that will further enhance the pipeline,” said Ms. Hamill. “I look
forward to engaging and leading Gilead’s talented commercial team and
partnering across the organization, to reach more people with unmet
medical needs around the world.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that
discovers, develops and commercializes innovative medicines in areas of
unmet medical need. The company strives to transform and simplify care
for people with life-threatening illnesses around the world. Gilead has
operations in more than 35 countries worldwide, with headquarters in
Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180828005831/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.Sung Lee, 650-524-7792InvestorsorMarni
Kottle, 650-522-5388Media
